Human TNFSF13 - APRIL ELISA Kit
$50.00 to US & $70.00 to Canada for most products. Final costs are calculated at checkout.
Background
Tumor necrosis factor ligand superfamily member 13(TNFSF13) also known as a proliferation-inducing ligand(APRIL) is a protein that in humans is encoded by the TNFSF13 gene. TNFSF13 has also been designated CD256(cluster of differentiation 256). The protein encoded by this gene is a member of the tumor necrosis factor ligand(TNF) ligand family. This protein is a ligand for TNFRSF17/BCMA, a member of the TNF receptor family. This protein and its receptor are both found to be important for B cell development. In vivo experiments suggest an important role for APRIL in the long-term survival of plasma cells in the bone marrow. Mice deficient in April showed a reduced ability to support plasma cell survival In vitro experiments suggested that this protein may be able to induce apoptosis through its interaction with other TNF receptor family proteins such asTNFRSF6/FAS and TNFRSF14/HVEM. Three alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported. The TNFSF13 gene lies 878 bp downstream of the TNFSF12 gene on chromosome 17p13.1.
Product Details
Target Details
Application Details
Formulation
Shipping & Handling
This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.